Role of fundus autofluorescence imaging in the management of submacular hemorrhage.
Humans
Male
Female
Retrospective Studies
Retinal Hemorrhage
/ diagnosis
Aged
Middle Aged
Fluorescein Angiography
/ methods
Tomography, Optical Coherence
/ methods
Adult
Aged, 80 and over
Adolescent
Visual Acuity
/ physiology
Fundus Oculi
Young Adult
Optical Imaging
/ methods
Angiogenesis Inhibitors
/ therapeutic use
Intravitreal Injections
Fundus autofluorescence
Pneumatic displacement
Retinal imaging
Submacular hemorrhage
Treatment outcome
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
13
12
2023
accepted:
04
10
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
8
10
2024
Statut:
epublish
Résumé
To evaluate the baseline characteristics of fundus autofluorescence (FAF) in patients with submacular hemorrhage (SMH). This retrospective study included patients diagnosed with treatment-naive, foveal-involving subretinal hemorrhage (size > 2-disc diameters) of any etiology, presenting between June 2017 and June 2023. Only cases with good-quality color fundus photographs, optical coherence tomography (OCT) scans, and blue-light FAF images at baseline were included. SMH imaging characteristics were documented and correlated with treatment outcomes. A successful treatment outcome was defined as the reduction, displacement or clearance of the SMH from beneath the fovea. Nineteen cases of SMH (13 males, 6 females), ranging from 14 to 85 years, were analyzed. Neovascular age-related macular degeneration (nAMD) was the most common etiology (n = 11, 58%). Baseline visual acuity ranged from 6/9 to counting fingers at ½ meter, with a median presentation time of 7 days from symptom onset (range: 1-57 days). Treatment success was observed in 13 eyes (68%). Hypoautofluoroscence on FAF was significantly associated with SMH resolution (p = 0.021). However, no association was found between treatment success and clinical hemorrhage characteristics (p = 0.222), OCT findings (p = 0.222), or specific treatments (p > 0.05). Hypoautofluoroscence on FAF was the sole predictor of treatment success, as demonstrated by Spearman's correlation (r = 0.637; p = 0.003) and linear regression analysis (p = 0.003). FAF, in conjunction with color fundus photography and OCT, may provide valuable insights for clinicians in formulating treatment strategies for patients with SMH. Hypoautofluoroscence on FAF was a significant predictor of successful SMH resolution in this study.
Identifiants
pubmed: 39379894
doi: 10.1186/s12886-024-03715-z
pii: 10.1186/s12886-024-03715-z
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
440Informations de copyright
© 2024. The Author(s).
Références
Kanukollu VM, Ahmad SS. Retinal Hemorrhage. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK560777/
Stanescu-Segall D, Balta F, Jackson TL. Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature. Surv Ophthalmol. 2016;61:18–32.
doi: 10.1016/j.survophthal.2015.04.004
pubmed: 26212151
Casini G, Loiudice P, Menchini M, Sartini F, De Cillà S, Figus M, et al. Traumatic submacular hemorrhage: available treatment options and synthesis of the literature. Int J Retin Vitr. 2019;5:48.
doi: 10.1186/s40942-019-0200-0
Lin T-C, Hwang D-K, Lee F-L, Chen S-J. Visual prognosis of massive submacular hemorrhage in polypoidal choroidal vasculopathy with or without combination treatment. J Chin Med Association. 2016;79:159–65.
doi: 10.1016/j.jcma.2015.11.004
Humayun M, Lewis H, Flynn HW, Sternberg P, Blumenkranz MS. Management of submacular hemorrhage associated with retinal arterial macroaneurysms. Am J Ophthalmol. 1998;126:358–61.
doi: 10.1016/S0002-9394(98)00090-7
pubmed: 9744368
Chang K-J, Cheng C-K, Peng C-H. Clinical characteristics and visual outcome of macular hemorrhage in pathological myopia with or without choroidal neovascularization. Taiwan J Ophthalmol. 2016;6:136–40.
doi: 10.1016/j.tjo.2016.05.007
pubmed: 29018729
Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94:762–73.
doi: 10.1016/0002-9394(82)90301-4
pubmed: 7180915
Scupola A, Coscas G, Soubrane G, Balestrazzi E. Natural history of Macular Subretinal Hemorrhage in Age-Related Macular Degeneration. Ophthalmologica. 1999;213:97–102.
doi: 10.1159/000027400
pubmed: 9885385
Yiu G, Mahmoud TH. Subretinal hemorrhage. Dev Ophthalmol. 2014;54:213–22.
doi: 10.1159/000360469
pubmed: 25196772
Meyer CH, Scholl HP, Eter N, Helb H, Holz FG. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol. 2008;86:490–4.
doi: 10.1111/j.1600-0420.2007.01125.x
pubmed: 18221499
Sacu S, Stifter E, Vécsei-Marlovits PV, Michels S, Schütze C, Prünte C, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye (Lond). 2009;23:1404–10.
doi: 10.1038/eye.2008.267
pubmed: 18756282
Guthoff R, Guthoff T, Meigen T, Goebel W, INTRAVITREOUS INJECTION OF, BEVACIZUMAB, TISSUE PLASMINOGEN ACTIVATOR, AND GAS IN THE TREATMENT OF SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION. Retina. 2011;31:36–40.
doi: 10.1097/IAE.0b013e3181e37884
pubmed: 20921929
Papavasileiou E, Steel DHW, Liazos E, McHugh D, Jackson TL, INTRAVITREAL TISSUE PLASMINOGEN ACTIVATOR PERFLUOROPROPANE. (C3F8), AND RANIBIZUMAB OR PHOTODYNAMIC THERAPY FOR SUBMACULAR HEMORRHAGE SECONDARY TO WET AGE-RELATED MACULAR DEGENERATION. Retina. 2013;33:846–53.
doi: 10.1097/IAE.0b013e318271f278
pubmed: 23400079
De Silva SR, Bindra MS. Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent. Eye. 2016;30:952–7.
doi: 10.1038/eye.2016.67
pubmed: 27080482
Karamitsos A, Papastavrou V, Ivanova T, Cottrell D, Stannard K, Karachrysafi S, et al. Management of acute submacular hemorrhage using intravitreal injection of tissue plasminogen activator and gas: a case series. SAGE Open Med Case Rep. 2020;8:2050313X20970337.
pubmed: 33240500
Bae K, Cho GE, Yoon JM, Kang SW. Optical coherence Tomographic features and prognosis of pneumatic displacement for Submacular Hemorrhage. PLoS ONE. 2016;11:e0168474.
doi: 10.1371/journal.pone.0168474
pubmed: 27992524
Yung M, Klufas MA, Sarraf D. Clinical applications of fundus autofluorescence in retinal disease. Int J Retin Vitr. 2016;2:12.
doi: 10.1186/s40942-016-0035-x
Fukuda Y, Nakao S, Kohno R-I, Ishikawa K, Shimokawa S, Shiose S, et al. Postoperative follow-up of submacular hemorrhage displacement treated with vitrectomy and subretinal injection of tissue plasminogen activator: ultrawide-field fundus autofluorescence imaging in gas-filled eyes. Jpn J Ophthalmol. 2022;66:264–70.
doi: 10.1007/s10384-022-00910-7
pubmed: 35260984
Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50:326–36.
doi: 10.3109/10409238.2015.1050550
pubmed: 26018600
pmcid: 4826570
Dean L, Biotechnology Information (US). Blood Groups and Red Cell Antigens [Internet]. Bethesda (MD): National Center for; 2005. Chapter 1, Blood and the cells it contains. https://www.ncbi.nlm.nih.gov/books/NBK2263/
Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol. 1997;42:195–213.
doi: 10.1016/S0039-6257(97)00089-1
pubmed: 9406367
Rishi E, Gopal L, Rishi P, Sengupta S, Sharma T. Submacular hemorrhage: a study amongst Indian eyes. Indian J Ophthalmol. 2012;60:521.
doi: 10.4103/0301-4738.103779
pubmed: 23202390
Barrera FJ, Yust B, Mimun LC, Nash KL, Tsin AT, Sardar DK. Optical and spectroscopic properties of human whole blood and plasma with and without Y2O3 and Nd3+:Y2O3 nanoparticles. Lasers Med Sci. 2013;28:1559–66.
doi: 10.1007/s10103-013-1268-7
pubmed: 23380906
Liu T, Zhang Y, Hou T, Xue Q, Wang L, Wang S. Sensitive fluorescent detection of fibrin based on the inner filter effect of gold nanoparticles. RSC Adv. 2017;7:23422–6.
doi: 10.1039/C7RA02422C
Gonçalves S, Santos NC, Martins-Silva J, Saldanha C. Fluorescence spectroscopy evaluation of fibrinogen–β-estradiol binding. J Photochem Photobiol B. 2007;86:170–6.
doi: 10.1016/j.jphotobiol.2006.09.001
pubmed: 17055287
Thompson JT, Sjaarda RN. Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement. Trans Am Ophthalmol Soc. 2005;103:98–107. discussion 107.
pubmed: 17057793
Grohmann C, Dimopoulos S, Bartz-Schmidt KU, Schindler P, Katz T, Spitzer MS, et al. Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods. Int J Retin Vitr. 2020;6:27.
doi: 10.1186/s40942-020-00228-x
Abdelkader E, Yip KP, Cornish KS. Pneumatic displacement of submacular haemorrhage. Saudi J Ophthalmol. 2016;30:221–6.
doi: 10.1016/j.sjopt.2016.10.002
pubmed: 28003779
Mizutani T, Yasukawa T, Ito Y, Takase A, Hirano Y, Yoshida M, et al. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2011;249:1153–7.
doi: 10.1007/s00417-011-1649-1
pubmed: 21445629
Sharma S, Kumar JB, Kim JE, Thordsen J, Dayani P, Ober M, et al. Pneumatic Displacement of Submacular Hemorrhage with Subretinal Air and tissue plasminogen activator: initial United States experience. Ophthalmol Retina. 2018;2:180–6.
doi: 10.1016/j.oret.2017.07.012
pubmed: 31047581
Collen D. Molecular mechanism of action of newer thrombolytic agents. J Am Coll Cardiol. 1987;10 5 Suppl B:11B-15B.
Chandler WL. Laboratory techniques in Fibrinolysis Testing. Transfusion Medicine and Hemostasis. Elsevier; 2019. pp. 865–8.